![]() This includes an estimated $123.6 million of COVID-19 related CleanCap revenue for the fourth quarter, which was $56.2 million lower than the same period in the prior year as CleanCap demand from COVID-19 vaccine manufacturers decreased. Nucleic Acid Production revenue was $189.3 million for the fourth quarter, an 11% decrease year-over-year.Revenue for the fourth quarter was $204.7 million, representing a 10% decrease over the same period in the prior year and was driven by the following: Revenue for the Fourth Quarter and Full Year 2022 “Entering 2023, we believe that we are incredibly well positioned to drive robust base business growth by innovating in ways that support our mRNA and cell and gene therapy customers’ discovery and clinical development programs.” These quarterly results include growth of 67% in our overall base business revenues, and growth of 101% in our non-COVID Nucleic Acid Production revenues,” said Carl Hull, Executive Chairman and Interim CEO of Maravai. “Maravai produced another solid quarter with total revenues reaching $204.7 million, capping off an exceptional year of record revenues and profits. Introduced 2023 revenue guidance range of $420.0 million to $460.0 million, with base business revenues, excluding COVID-19 related CleanCap revenues, expected to grow in excess of 20%.Completed the acquisition of Alphazyme, LLC, a privately-held, founder-led OEM provider of custom, scalable molecular biology enzymes, servicing customers in the genetic analysis and nucleic acid synthesis markets and,.Launched new Office of Science and Innovation, led by Dr.Named to the 2022 Deloitte Technology Fast 500™ List of Fastest-Growing Companies in North America.Expanded MockV® product offering with new kit that predicts retroviral particle clearance in biopharmaceutical manufacturing.Annual revenue of $883.0 million, Net income of $490.7 million and Adjusted fully diluted EPS of $1.80.Quarterly revenue of $204.7 million, Net income of $87.4 million, and Adjusted fully diluted earnings per share (EPS) of $0.35.(Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter and full year ended December 31, 2022, together with other business updates. 22, 2023 (GLOBE NEWSWIRE) - Maravai LifeSciences Holdings, Inc. Base business revenues, excluding COVID-19 related CleanCap® revenues, were up 67% in the fourth quarter and up 17% for the full yearĪnnounces acquisition of privately-held Alphazyme, LLC, adding critical enzyme manufacturing capabilities to Maravai’s Nucleic Acid Production Segment ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |